ライフサイエンスコーパス: cell-free DNA

1 or each case and detected by qPCR within the cell-free DNA.

2 nology was also used to remove contaminating cell-free DNA.

3 crobial samples and removal of contaminating cell-free DNA.

4 t DNA extracted from plasma reflected fungal cell-free DNA.

5 performed to identify the tissue sources of cell-free DNA.

6 overy tool for fragmentation analyses and in cell-free DNA.

7 rotic plaques via an increase of circulating cell-free DNA.

8 ng shallow whole genome sequencing (sWGS) of cell-free DNA.

9 oplets to represent circulating viral DNA or cell-free DNA.

10 .17 vs. 0.77) and the level of donor-derived cell-free DNA (0.31% vs. 0.82%).

11 es by parallel sequencing of maternal plasma cell-free DNA, 3 aberrant genome representation (GR) pro

12 proach to evaluate fragmentation patterns of cell-free DNA across the genome, and found that profiles

13 for cell growth inhibition and -log AE (AE = cell-free DNA alkylation efficiency) were observed, with

14 Combining our approach with mutation-based cell-free DNA analyses detected 91% of patients with can

15 racted using a 32-gauge needle and underwent cell-free DNA analysis.

16 Both release of cell-free DNA and apoptosis could be significantly reduc

17 Assays measuring circulating cell-free DNA and cell-free tumour DNA are emerging as c

18 ome sequencing of post-mortem plasma-derived cell-free DNA and eight frozen metastatic cancer tissues

19 n knowledge of the methylomes of circulating cell-free DNA and its cellular contributors.

20 e analyses highlight important properties of cell-free DNA and provide a proof-of-principle approach

21 Markov Model, to predict DNA methylation of cell-free DNA and, therefore, tissues-of-origin, directl

22 oRNA, circulating tumor cells, exosomes, and cell-free DNA, and discuss the opportunity of utilizing

23 NA-elastase and histone-elastase complexes), cell-free DNA, and neutrophil biomarkers were quantified

24 uding changes in circulating microparticles, cell-free DNA, and neutrophil extracellular traps.

25 ics of the origins and molecular features of cell-free DNA are poorly understood.

26 mparing placenta to non-pregnant circulating cell-free DNA are recapitulated in pregnant circulating

27 Abundance of tumor-derived DNA in total cell-free DNA, as measured by TP53 mutant allele frequen

28 Plasma cell-free DNA at baseline showed ERBB2 (HER2) amplificat

29 ional blood cultures were compared to plasma cell-free DNA-based 16S ribosomal RNA (rRNA) gene polyme

30 Complementary to existing screening tests, cell-free DNA-based multicancer early detection (MCED) t

31 ian proportion of tumor-derived DNA in total cell-free DNA before treatment was 0.07%, indicating tha

32 2AX activation was in the same rank order as cell-free DNA break induction, although the amount of br

33 , which exploits the diagnostic potential of cell-free DNA by determining not only the presence but a

34 Our results demonstrate that cell-free DNA can be used to detect an organ-specific si

35 However, circulating cell-free DNA carrying tumor-specific alterations (circu

36 Although Ov16R failed to detect circulating cell-free DNA (ccfDNA) in the plasma of individuals infe

37 Analysis of circulating cell-free DNA (ccfDNA) is a suitable tool for detecting

38 For example, circulating cell-free DNA (ccfDNA) sequencing for cancer monitoring

39 ing and whole-genome bisulfite sequencing of cell free DNA (cfDNA) and of matched metastatic tumor bi

40 ssociated copy number variation (CNV) in the cell free DNA (cfDNA) fraction of patient blood plasma.

41 Cell free DNA (cfDNA) has received increasing attention

42 of circulating tumor DNA (ctDNA) from plasma cell free DNA (cfDNA) has shown promise for diagnosis, t

43 However, the plasma cell free DNA (cfDNA) level can be low and the fraction

44 ate somatic variant detection in circulating cell free DNA (cfDNA) NGS data requires filtering strate

45 atic disease, deep sequencing of circulating cell free DNA (cfDNA) obtained from patient's blood yiel

46 Circulating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated w

47 1047R) in circulating tumor cells (CTCs) and cell free DNA (cfDNA).

48 lood or urine and sequencing the circulating cell free DNA (cfDNA).

49 ively parallel sequencing of maternal plasma cell-free DNA (cfDNA testing) accurately detects fetal a

50 the utility of high-throughput sequencing of cell-free DNA (cfDNA) after bisulfite conversion to map

51 unities for detection of residual disease in cell-free DNA (cfDNA) after surgery but may be confounde

52 Cell-free DNA (cfDNA) analysis is an attractive approach

53 ging technologies are reliant on circulating cell-free DNA (cfDNA) and cell-free RNA (cfRNA) applicat

54 ts against IBD by scavenging proinflammatory cell-free DNA (cfDNA) and reactive oxygen species (ROS).

55 on status between tumor-specific circulating cell-free DNA (cfDNA) and tumor tissue, and the evaluati

56 , yet the nature and regulation of antigenic cell-free DNA (cfDNA) are poorly understood.

57 A cell-free DNA (cfDNA) assay would be a promising approac

58 Circulating cell-free DNA (cfDNA) assays for monitoring individuals

59 on (MCD) assays, we desire an extra 80 mL of cell-free DNA (cfDNA) blood, but this much extra blood i

60 We hypothesize that targeting of circulating cell-free DNA (cfDNA) by DNases might represent a feasib

61 Diagnostically informative microbial cell-free DNA (cfDNA) can be detected from blood plasma

62 Detection of microbial cell-free DNA (cfDNA) circulating in the bloodstream has

63 Elevation of circulating cell-free DNA (cfDNA) concentration has been shown to be

64 sis or necrosis, and the load of circulating cell-free DNA (cfDNA) correlates with tumor staging and

65 Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profili

66 Fungal cell-free DNA (cfDNA) detection in plasma is a novel tes

67 Cell-free DNA (cfDNA) exists in plasma and can be measur

68 Cell-free DNA (cfDNA) extracted from maternal plasma was

69 Here, we demonstrated the use of circulating cell-free DNA (cfDNA) for detection of tissue turnover a

70 g the effectiveness of utilizing circulating cell-free DNA (cfDNA) for disease screening remains a ch

71 Circulating cell-free DNA (cfDNA) fragments are a biological analyte

72 Cell-free DNA (cfDNA) fragments are released into the bl

73 ellular damages after liver transplants from cell-free DNA (cfDNA) fragments released from dying cell

74 er 16, 2014, to August 26, 2015, we analyzed cell-free DNA (cfDNA) from baseline plasma samples from

75 Detection of amplification in cell-free DNA (cfDNA) from blood is strongly associated

76 Disease diagnosis using cell-free DNA (cfDNA) has been an active research field

77 Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method t

78 patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimall

79 Circulating cell-free DNA (cfDNA) has the potential to be a specific

80 Cell-free DNA (cfDNA) has the potential to inform tumor

81 measured by (18)F-FDG PET/CT and circulating cell-free DNA (cfDNA) have been separately validated as

82 ng for aneuploidy by analysis of circulating cell-free DNA (cfDNA) have shown high sensitivity and sp

83 Here, we show that cell-free DNA (cfDNA) in blood is a versatile analyte fo

84 Cell-free DNA (cfDNA) in blood, viewed as a surrogate fo

85 Quantification of cell-free DNA (cfDNA) in circulating blood derived from

86 Detection of circulating fungal cell-free DNA (cfDNA) in plasma and serum by polymerase

87 Genomic analyses of cell-free DNA (cfDNA) in plasma are enabling noninvasive

88 Genome-wide fragmentation patterns in cell-free DNA (cfDNA) in plasma are strongly influenced

89 hat detection of Borrelia burgdorferi (B.b.) cell-free DNA (cfDNA) in plasma can improve diagnosis of

90 Measuring the methylation status of cell-free DNA (cfDNA) in plasma holds great potential fo

91 lung transplant recipients by sequencing of cell-free DNA (cfDNA) in plasma.

92 However, low quantities of cell-free DNA (cfDNA) in the blood and sequencing artifa

93 Circulating cell-free DNA (cfDNA) in the bloodstream originates from

94 Cell-free DNA (cfDNA) in the circulating blood plasma of

95 ribed the observation of increased levels of cell-free DNA (cfDNA) in the serum of patients with canc

96 Cell-free DNA (cfDNA) in urine is a promising analyte fo

97 Cell-free DNA (cfDNA) is a noninvasive marker of cellula

98 Circulating cell-free DNA (cfDNA) is a promising biomarker for the d

99 Cell-free DNA (cfDNA) is attractive for many application

100 next-generation sequencing (mNGS) of plasma cell-free DNA (cfDNA) is commercially available, but its

101 Circulating cell-free DNA (cfDNA) is emerging as a powerful monitori

102 Circulating cell-free DNA (cfDNA) is emerging as an avenue for cance

103 Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166

104 Cell-free DNA (cfDNA) is released from injured cells and

105 Cell-free DNA (cfDNA) is shed into the blood by tumor ce

106 e of Kaposi sarcoma herpesvirus sequences in cell-free DNA (cfDNA) isolated from the blood of patient

107 After establishing the correlation of cell-free DNA (cfDNA) level with periodontitis in patien

108 s across 29 tumour classes using circulating cell-free DNA (cfDNA) methylation patterns.

109 currently implemented, unlike non-SCLC where cell-free DNA (cfDNA) mutation profiling in the blood ha

110 Circulating cell-free DNA (cfDNA) of cardiomyocyte origin is present

111 esent at very low concentrations compared to cell-free DNA (cfDNA) of non-tumor origin.

112 hat the majority of somatic mutations in the cell-free DNA (cfDNA) of patients with lung cancer and o

113 een circulating tumor cells (CTCs) or plasma cell-free DNA (cfDNA) on one side and a comprehensive ra

114 Cell-free DNA (cfDNA) present in the bloodstream or othe

115 rived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the vari

116 r follow-up investigations, such as prenatal cell-free DNA (cfDNA) screening or cytogenetic testing.

117 arrangements would not have been detected by cell-free DNA (cfDNA) screening.

118 Cell-free DNA (cfDNA) sequence analysis to screen for fe

119 Cell-free DNA (cfDNA) sequencing is becoming widely adop

120 Although cell-free DNA (cfDNA) shows promise in detecting cancer

121 genetic mutants (EGFR T790M) with precision cell-free DNA (cfDNA) standards.

122 eports the performance of an optimized urine cell-free DNA (cfDNA) test using sequence-specific purif

123 Cell-free DNA (cfDNA) testing for fetal trisomy is highl

124 Cell-free DNA (cfDNA) testing is increasingly used in th

125 Cell-free DNA (cfDNA) tests use small amounts of DNA in

126 e found in an unbiased manner in circulating cell-free DNA (cfDNA) to predict treatment response in H

127 Cell-free DNA (cfDNA) was isolated from 291 plasma sampl

128 Cell-free DNA (cfDNA) was isolated from 6 AH samples fro

129 Cellular and cell-free DNA (cfDNA) were isolated from each lavage.

130 suggested that liquid biopsy (specifically, cell-free DNA (cfDNA)) may better capture the heterogene

131 Circulating donor-derived cell-free DNA (cfDNA), a minimally invasive diagnostic t

132 le-nucleotide variants (SNVs) in circulating cell-free DNA (cfDNA), a mixture of DNA molecules origin

133 ion, immature granulocyte (IG) count, plasma cell-free DNA (cfDNA), and plasma citrullinated histone

134 lored to infer gene expression profiles from cell-free DNA (cfDNA), but current fragmentomic methods

135 A tumor-derived fraction of circulating cell-free DNA (cfDNA), isolated from blood samples, cont

136 By deep sequencing cell-free DNA (cfDNA), isolated from circulating blood p

137 omarkers, circulating tumor cells (CTCs) and cell-free DNA (cfDNA), with regard to pancreatic ductal

138 A potential source of inflammation is cell-free DNA (cfDNA), yet the cellular origins, molecul

139 (AH) is an alternate source of tumor-derived cell-free DNA (cfDNA).

140 opsy have focused on the analysis of nuclear cell-free DNA (cfDNA).

141 ay to identify patients with RCC using urine cell-free DNA (cfDNA; AUROC of 0.86).

142 Cell-free DNAs (cfDNAs) were analyzed in a RET-mutant me

143 Cell-free DNA circulating in serum is a candidate molecu

144 We analyzed cell-free DNA circulating in the blood of heart transpla

145 p Sequencing, [CAPP-Seq]) analyses of plasma cell-free DNA collected from 45 patients before and afte

146 ole genome DNA lysed from cell line and from cell-free DNA collected from cell culture media.

147 irculating leukocytes) and acellular (plasma cell-free DNA) compartments of peripheral blood to clini

148 NA are recapitulated in pregnant circulating cell-free DNA, confirming the ability to detect differen

149 l of the metabolites, including amino acids, cell-free DNA, creatinine, and bilirubin, assigned for t

150 present FinaleDB (FragmentatIoN AnaLysis of cEll-free DNA DataBase), a comprehensive database to hos

151 Data on elevation in donor-derived cell-free DNA (dd-cfDNA) and CAV in the absence of rejec

152 Donor-derived cell-free DNA (dd-cfDNA) fraction and quantity have both

153 anti-HLA antibodies (DSA) and donor-derived cell-free DNA (dd-cfDNA) have lead to substantial progre

154 The copy number of donor-derived cell-free DNA (dd-cfDNA) in blood correlates with acute

155 Donor-derived cell-free DNA (dd-cfDNA) in the blood circulation is an

156 sing marker is the presence of donor-derived cell-free DNA (dd-cfDNA) in the urine or blood of transp

157 Donor-derived cell-free DNA (dd-cfDNA) is a biomarker that enables the

158 Donor-derived cell-free DNA (dd-cfDNA) is a biomarker validated to det

159 Donor-derived cell-free DNA (dd-cfDNA) is a dynamic, noninvasive bioma

160 Circulating graft-derived cell-free DNA (dd-cfDNA) is a new marker of cardiac allo

161 Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allogr

162 Donor-derived cell-free DNA (dd-cfDNA) is a promising biomarker of acu

163 Donor-derived cell-free DNA (dd-cfDNA) is an emerging noninvasive biom

164 Donor-derived cell-free DNA (dd-cfDNA) is an important molecular marke

165 Donor-derived cell-free DNA (dd-cfDNA) levels were measured approximat

166 loped a pilot study to explore donor-derived cell-free DNA (dd-cfDNA) performance in predicting biops

167 Donor-derived cell-free DNA (dd-cfDNA) shows promise as an early indic

168 ods present an opportunity for donor-derived cell-free DNA (dd-cfDNA), which can accurately and rapid

169 idity of lab-based testing for donor-derived cell-free DNA (dd-cfDNA).

170 Donor-derived cell-free DNA (ddcfDNA) has been proposed as one such tr

171 Donor-derived cell-free DNA (ddcfDNA) is a promising minimally invasiv

172 Donor-derived cell-free DNA (ddcfDNA) is increasingly used in clinical

173 (V600E) allele load, assessed as circulating cell-free DNA, decreased after starting VMF but remained

174 sma DNA fragmentomics is an emerging area in cell-free DNA diagnostics and research.

175 durable responses occurred in patients with cell-free DNA ERBB2 amplification.

176 of a variety of human genetic diseases using cell-free DNA extracted from maternal plasma samples in

177 Early cancer detection by cell-free DNA faces multiple challenges: low fraction of

178 s in the context of prenatal diagnosis using cell free DNA for monogenic diseases that segregate in a

179 recommendations on the use of donor-derived cell-free DNA for monitoring pancreas graft recipients a

180 the classifier to include information about cell-free DNA fragment size and abundance across the gen

181 nfers accessibility of TF binding sites from cell-free DNA fragmentation patterns.

182 Liquid biopsy analysis of circulating cell-free DNA fragments in the patients' blood can monit

183 methylcytosine (5hmC) changes in circulating cell free DNA from a PDAC cohort (n = 64) in comparison

184 265P mutation was detected in cell-based and cell-free DNA from 15 (83%) of 18 eyes with biopsy-confi

185 Circulating cell-free DNA from blood plasma of cancer patients can b

186 next-generation sequencing (mNGS) test using cell-free DNA from body fluids to identify pathogens.

187 Because cell-free DNA from brain and spinal cord tumors cannot u

188 We sequenced 341 cancer-associated genes in cell-free DNA from cerebrospinal fluid (CSF) obtained th

189 ive diagnosis of fetal genetic disease using cell-free DNA from maternal plasma samples obtained in t

190 t of unmatched samples including circulating cell-free DNA from non-pregnant and pregnant female dono

191 Here, analysis of tumor samples and cell-free DNA from patients with advanced prostate cance

192 ve, as well as single genetic loci from pure cell-free DNA from peripheral blood.

193 ingle-stranded DNA sequencing (ssDNA-seq) of cell-free DNA from plasma and other bodily fluids is a p

194 bacteriophages and their bacterial hosts in cell-free DNA from plasma samples.

195 gh massive shotgun sequencing of circulating cell-free DNA from the blood, we identified hundreds of

196 d observed significantly increased levels of cell-free DNA from the donor genome at times when an end

197 Graft-derived cell-free DNA (gdcfDNA) analysis is an emerging tool for

198 LINE-1 hypomethylation of cell-free DNA has been described as an epigenetic biomar

199 Plasma genotyping of cell-free DNA has the potential to allow for rapid nonin

200 , such as deep sequencing and utilization of cell-free DNA, have improved diagnosis and refined both

201 placental apoptosis/necrosis and release of cell-free DNA, hence confirming that maternal serum/plas

202 thylation and fragment length in circulating cell-free DNA, identify differentially methylated region

203 ed that pristane-injected mice had increased cell free DNA in serum, which was not impacted by inhibi

204 ted methods, sequencing identified microbial cell-free DNA in 62, likely derived from commensal organ

205 ns and the tissue-of-origin of tumor-derived cell-free DNA in a blood sample using genome-wide DNA me

206 In an analysis of cell-free DNA in blood samples from patients who underwe

207 Cell-free DNA in human blood plasma (cfDNA) is now widel

208 Detection of cell-free DNA in liquid biopsies offers great potential

209 ations and the classification of tumors from cell-free DNA in liquid biopsies.

210 non-invasive methods of fetal testing using cell-free DNA in maternal plasma.

211 redictive impact of ultra-deep sequencing of cell-free DNA in patients before and after cystectomy an

212 est that identifies and quantifies microbial cell-free DNA in plasma from 1,250 clinically relevant b

213 ext-generation sequencing in tumor tissue or cell-free DNA in plasma to detect PIK3CA mutations.

214 We used sequencing of cell-free DNA in plasma to investigate drug-virome inter

215 atic tissues of mice and increased levels of cell-free DNA in plasma.

216 Cell-free DNA in serum or plasma is emerging as a useful

217 Cell-free DNA in the blood provides a non-invasive diagn

218 This testing utilizes cell-free DNA in the maternal circulation to predict fet

219 The concentration of beta-globin cell-free DNA in the supernatant, measured using real-ti

220 , nucleated cells release DNA, resulting in "cell-free" DNA in plasma (cfDNA).

221 ostics using free circulating nucleic acids (cell-free DNA) in plasma samples of septic patients.

222 Detection of cell-free DNA (including HPV DNA) in blood has great pro

223 Cell-free DNA is a promising biomarker for monitoring th

224 Cell-free DNA is present in different biological fluids

225 Circulating cell-free DNA is primarily derived from hematopoietic ce

226 Assay results obtained with serum cell-free DNA isolated from a cohort of children aged 1

227 hus, this study analyzed the effect of tumor cell-free DNA, isolated from the blood of prostate cance

228 A PDL-1 CPS score of 5 or greater, cell-free DNA level less than the median, and T cell rep

229 of CEPs (P < 0.05) and led to a decrease in cell-free DNA levels (P < 0.05).

230 Cell-free DNA levels and tissue sources differed by nati

231 t MDS genome would be a major contributor to cell-free DNA levels in MDS patients as a result of inef

232 Donor-derived cell-free DNA levels strongly correlated with allograft

233 othelial precursors (CEP) and tumor-specific cell-free DNA levels were assessed.

234 ructural motifs which relies on splint-free, cell-free DNA ligations and recycling of side-products b

235 ural variants as highly sensitive endogenous cell-free DNA markers, enabling the relative abundance m

236 hat maternal serum/plasma concen-trations of cell-free DNA may act as a biomarker of trophoblast well

237 Biomarkers such as donor-derived cell-free DNA may enable personalized immunosuppression

238 Concurrently, novel applications of cell-free DNA may guide perioperative management strateg

239 ficient differentiation between cellular and cell-free DNA may have confounded analyses of genome-wid

240 Emerging evidence suggests that microbial cell-free DNA (mcfDNA) and metagenomic testing can enhan

241 MPORTANCEMetagenomic sequencing of microbial cell-free DNA (mcfDNA) enables the identification and qu

242 d to examine the ability of a novel panel of cell-free DNA methylation markers to predict survival ou

243 tect differential methylation in circulating cell-free DNA mixtures.

244 s multiple challenges: low fraction of tumor cell-free DNA, molecular heterogeneity of cancer, and sa

245 Detection of actionable drug targets in cell-free DNA, more comprehensive molecular profiling in

246 d mortality, whereas other NET assays (e.g., cell-free DNA, myeloperoxidase, and myeloperoxidase-DNA

247 Additionally, levels of cell-free DNA, neutrophil gelatinase-associated lipocali

248 te that TP53 mutations appear in circulating cell-free DNA obtained from patients with de-differentia

249 tissue-of-origin mapping in the circulating cell-free DNA of 59 patients with lung or colorectal can

250 The study revealed that cell-free DNA of HHV-6 was detected more frequently in b

251 lecular diagnostics based on the analysis of cell-free DNA or single-nucleotide variants (SNVs) out o

252 Pathogen cell-free DNA (pcfDNA) in blood and urine is an attracti

253 e (ccf) fetal DNA comprises 3-20% of all the cell-free DNA present in maternal plasma.

254 htened degree of tissue injury with elevated cell-free DNA, primarily originating from innate immune

255 these trials by applying single-cell RNA and cell-free DNA profiling to longitudinal cerebrospinal fl

256 To achieve this, we performed cell-free DNA quantification and characterization assays

257 Fetal cells and cell-free DNA reach the maternal circulation during norm

258 A replication by geminin that is observed in cell-free DNA replication extracts is reversed by the ad

259 We exploit an improved mammalian cell-free DNA replication system to analyse quiescence a

260 In a cell-free DNA replication system, extracts from BLM-trea

261 n of cellular DNA replication in a mammalian cell-free DNA replication system.

262 binding domain of ORC1 are unable to support cell-free DNA replication.

263 Fragmentomics features of cell-free DNA represent promising non-invasive biomarker

264 mes of placenta and non-pregnant circulating cell-free DNA reveal many of the 51,259 identified diffe

265 Analysis of DNA methylation in cell-free DNA reveals clinically relevant biomarkers but

266 es in understanding circulating tumor cells, cell-free DNA/RNA, and exosomes in blood have laid a sol

267 ic analysis of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome analysis of seven

268 lyze whole genome sequencing data for >1,000 cell-free DNA samples from cancer patients and healthy c

269 2878) and genomic data from paired tumor and cell-free DNA samples revealing loss of heterozygosity.

270 ify and classify tumor signals in tissue and cell-free DNA samples.

271 e low proportion of tumor-derived DNA in the cell-free DNA scenarios.

272 liquid biomarkers identified from methylated cell-free DNA sequenced in plasma were used to generate

273 Furthermore, post-mortem plasma cell-free DNA sequencing (liquid autopsy) can be a novel

274 luated the performance of a plasma microbial cell-free DNA sequencing (mcfDNA-Seq) test for diagnosin

275 ve method for assessing TF activity based on cell-free DNA sequencing and nucleosome footprint analys

276 Molecular response measured by cell-free DNA sequencing at day 7 after infusion was sig

277 ptomatic pregnant women who underwent plasma cell-free DNA sequencing for clinical prenatal aneuploid

278 We show that maternal plasma cell-free DNA sequencing for noninvasive prenatal testin

279 ual care in 52/173 (30.1%), plasma microbial cell-free DNA sequencing in 49/173 (28.3%) and the combi

280 Microbial cell-free DNA sequencing offers the potential to non-inv

281 Cell-free DNA shed by cancer cells has been shown to be

282 ottleneck by developing a workflow combining cell-free DNA template generation, cell-free protein syn

283 For example, in one study, cell-free DNA testing reliably detected mutations in 14

284 Furthermore, we show that cell-free DNA TF profiling is capable of detection of ea

285 discovered fragmentation disparities in the cell-free DNA that characterize lymphoma-derived ctDNA a

286 ed a blood-based biomarker assay using tumor cell-free DNA to measure systemic tumor burden longitudi

287 ited for liquid biopsy applications based on cell-free DNA to stratify patients and monitor disease p

288 rimary brain tumor in adults, examination of cell-free DNA uncovered patterns of tumor evolution, inc

289 ically and by determination of donor-derived cell-free DNA) until last follow-up at 23 months after C

290 Furthermore, elevated cell-free DNA was associated with shorter time to first

291 Therefore, tumor cell-free DNA was capable of altering the receptor cell

292 points within the 28-day observation period, cell-free DNA was isolated and analyzed by next-generati

293 Cell-free DNA was isolated and the MCED test performed b

294 Cell-free DNA was isolated from 122 of 125 plasma sample

295 Cell-free DNA was isolated from the AH, and sequencing l

296 Cell-free DNA was quantified in plasma samples.

297 The post-mortem plasma cell-free DNA was successfully sequenced and 344 mutatio

298 cific anti-HLA antibodies, and donor-derived cell-free DNA were monitored in KTRs undergoing MPA with

299 rst confirmed that substantial quantities of cell-free DNA were present in the post-mortem plasma of

300 We directly sequenced cell-free DNA with high-throughput shotgun sequencing te